Molecular Therapy — Nucleic Acids · 2020 · 30 citations · 21 references
PharmacyOncologyPharmaceuticsDrug DeliveryMolecular ImagingMolecular OncologyCancer NanomedicineLigand BindingNanocarriers For TherapeuticsNanomedicineNucleic Acid DeliveryTargeting LigandsAptamer - Target Binding AffinityAptamer SpecificityAptamer Targeting LigandsCancer Targeting LigandsMultivalent Ligand BindingProstate-specific Membrane Antigen TargetingTumor Targeting LigandsTumor Targeting Specificity
applications it is often desirable to multimerize the aptamers in order to increase their binding strength and overall specificity. Additional functionalities, such as imaging and therapeutic agents, as well as pharmacokinetic modifiers, need to be attached in a stoichiometric fashion. Herein, we present a robust method for assembly of up to three aptamers and a fluorophore in a single well-defined nanostructure. The process is entirely modular and can be applied to any aptamer requiring only a single reactive "click handle." Multimerization of two aptamers, A9g and GL21.T, previously shown to target cancer cells, led to a strong increase in cell uptake. A similar effect was observed for the prostate-specific membrane antigen (PSMA)-targeting A9g aptamer in mice where multivalent aptamer binding led to increased tumor specificity. Altogether, this method provides a platform for multimerization of aptamers with advantages in terms of combinatorial screening capacity and multifunctional design of nanomedicine.
21
Prostate-specific membrane antigen expression in normal and malignant human tissues.
Donald Silver, I Pellicer, W R Fair et al. · PubMed · 1997 · 1.5K citations
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
James O McNamara, Eran R. Andrechek, Yong Wang et al. · Nature Biotechnology · 2006 · 994 citations
Nanoparticle-Aptamer Bioconjugates
Omid C. Farokhzad, Sangyong Jon, Ali Khademhosseini et al. · Cancer Research · 2004 · 886 citations · Full text